منابع مشابه
New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study
OBJECTIVE New oral anticoagulants (NOACs) are increasingly used both for prevention of stroke in non-valvular atrial fibrillation (NVAF) and the treatment of venous thromboembolism (VTE). In this study, we aimed to evaluate the current patterns of NOACs treatment in Turkey. Moreover, demographic and clinical parameters and bleeding and/or embolic events under NOACs treatment were analyzed. ME...
متن کاملCurrent Perspective on Use of NOAC in Clinical Practice in India.
Oral vitamin K antagonists (VKA) such as warfarin have been the mainstay of therapy for stroke prevention in patients with non valvular atrial fibrillation (NVAF) while low-molecular-weight heparin, fondaparinux and adjusted-dose warfarin or aspirin have been routinely used for thromboembolism (VTE) prophylaxis in patients undergoing total hip or knee replacement. However, VKAs are associated w...
متن کاملRates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.
Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation and treatment of venous thromboembolism, but little is known about rivaroxaban-related bleeding complications in daily care. Using data from a prospective, noninterventional oral anticoagulation registry of daily care patients (Dresden NOAC registry), we analyzed rates, management, and outcome of rivaroxaba...
متن کاملAntithyroid Drugs
The thionamide drugs, i.e. carbimazole and its metabolite methimazole (MMI), andpropylthiouracil (PTU) have extensively been used in the management of various forms ofhyperthyroidism over the past eight decades. This review aims to summarize different aspectsof these outstanding medications. Thionamides have shown their own acceptable efficacy andeven safety profiles in ...
متن کاملEstimating the Quantitative Demand of NOAC Antidote Doses on Stroke Units.
BACKGROUND The first specific antidote for non-vitamin K antagonist oral anticoagulants (NOAC) has recently been approved. NOAC antidotes will allow specific treatment for 2 hitherto problematic patient groups: patients with oral anticoagulant therapy (OAT)-associated intracerebral hemorrhage (ICH) and maybe also thrombolysis candidates presenting on oral anticoagulation (OAT). We aimed to esti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Dental Journal
سال: 2016
ISSN: 0007-0610,1476-5373
DOI: 10.1038/sj.bdj.2016.885